Form OTIMM-2: Chemical Use Log for Clinical Trials Using Terramycin 343® under INAD 9033

INSTRUCTIONS

1. Investigator should initiate a new form OTIMM-2 **immediately** upon receipt of each shipment of Oxytetracycline for Immersion.
2. Form OTIMM-2 should be updated whenever drug is used, transferred, or discarded.
3. Investigator should save all copies of this form until the end of the calendar year, at which time they should maintain all originals on file and send one copy of the completed form(s) to their Study Monitor. Within 10 days of receipt, the Study Monitor will ensure accuracy and send a copy to the AADAP Office for inclusion in the permanent file.
4. **Note:** Both Investigator and Study Monitor should sign and date Form OTIMM-2.

Qty of OTIMM from previous page (gm) _____ Facility _____ Reporting individual _____

Date	Amount of new TM-343 received (gm)	Lot number of TM-343 received	Study Number	Amount of TM-343 used in treatment (gm)	TM-343 transferred (gm)	TM-343 discarded (gm)	TM-343 remaining on hand (gm)	Inventory by (Initials)
	xxxx	xxxx						
	xxxx	xxxx						
	xxxx	xxxx						
	xxxx	xxxx						
	xxxx	xxxx						
	xxxx	xxxx						
	xxxx	xxxx						
	xxxx	xxxx						
	xxxx	xxxx						
	xxxx	xxxx						
	xxxx	xxxx						
	xxxx	xxxx						
	xxxx	xxxx						

Date Prepared: _____ **Investigator:** _____

Date Reviewed: _____ **Study Monitor:** _____